SPARC sold its Rare Paediatric Disease Priority Review Voucher (PRV) for US $195 million.

Sun Pharma Advanced Research Company LimitedSPARC · Filed with the exchange

This strategic sale aims to accelerate pipeline development and strengthen its external innovation strategy, utilizing funds from its Sezaby® approval.

Read the original filing(PDF)

No comments yet. Be the first.

More from Sun Pharma Advanced Research Company Limited

All announcements

Updates13-08-2026
General Updates
Others11-08-2026
Copy of Newspaper Publication
Others10-08-2026
Shareholders meeting
Others10-08-2026
Monitoring Agency Report
Board Meeting10-08-2026
Outcome of Board Meeting
Board Meeting10-08-2026
Outcome of Board Meeting

Free

Track this company, and every filing it makes

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

Create a free account

No card needed. Takes about a minute.